ArticleJournal of agricultural and food chemistry2025
Trilobatin, a Naturally Occurring GPR158 Ligand, Alleviates Depressive-like Behavior by Promoting Mitophagy.
Article in Journal of agricultural and food chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The G-protein-coupled receptor (GPR158), an orphan receptor, is highly expressed in the medial prefrontal cortex (mPFC) and identified as a novel therapeutic target for depression. Trilobatin is a naturally occurring food additive with potent neuroprotective properties. However, its pharmacological effects and molecular mechanisms against depression remain unknown. Therefore, we explored whether trilobatin alleviates depression by targeting GPR158. Our results indicated that trilobatin alleviated chronic unpredictable mild stress (CUMS)-induced depressive-like behavior in mice. Mitophagy contributed to the antidepressant-like effect of trilobatin, as evidenced by the qRT-PCR array. Furthermore, trilobatin up-regulated autophagy-associated protein expression, restored mitochondrial dynamic balance, and inhibited oxidative stress of mPFC in mice after CUMS insult and in corticosterone-induced primary neuron injury. Intriguingly, trilobatin directly bound to GPR158 and decreased its level of protein expression. GPR158 deficiency attenuated depressive-like behavior through promoting mitophagy, while the antidepressant effect of trilobatin was strengthened in GPR158-deficient mice. Our findings highlight that GPR158-mediated mitophagy acts as a crucial pharmacological target for depression and reveal a new-found pharmacological property of trilobatin: serving as a novel naturally occurring ligand of GPR158 to safeguard from depression by oxidative stress by promoting mitophagy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.